Publicações - 1998

Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits.

Lobato L, Beirao I, Guimaraes SM, Droz D, Guimaraes S, Grunfeld JP, Noel LH.

Department of Nephrology, Hospital Geral de Santo Antonio, Porto, Portugal.

Am J Kidney Dis. 1998; 31(6): 940-6

Renal amyloidosis has been considered rare and late in the evolution of the transthyretin (TTR) familial amyloid polyneuropathy (FAP) of the Portuguese type (type I). Renal biopsy has been performed systematically in 14 patients with FAP type I before liver transplantation. In all patients, TTR Met30 mutation was shown. Seven had proteinuria or abnormal microalbuminuria, whereas seven others had no urinary abnormalities. All had renal amyloid deposition predominantly in the medulla. Glomerular and vascular involvement was more prominent in patients with urinary abnormalities. Patients with the most extensive renal lesions represented a subgroup with a low score of polyneuropathy disability, a high prevalence of nephropathy in the proband generation, or a late onset for relatives with nephropathy. Immunohistochemistry studies showed that the amyloid substance corresponded to transthyretin. We have shown that renal TTR-derived amyloid deposition is common in patients with FAP type I, even in the absence of urinary abnormalities. The clinical presentation of nephropathy is not a late occurrence in the disease.

PMID: 9631837 [PubMed - indexed for MEDLINE]

Early destructive spondyloarthropathy from combined beta2-microglobulin and transthyretin Met30 amyloidosis in a dialysed patient.

Beirao I, Lobato L, Guimaraes SM, Cardoso P, Costa PM, Coelho T, Rocha G, Guimaraes S.

Department of Nephrology, Hospital Geral de Santo Antonio, and Centro de Estudos de Paramiloidose, INSA, Porto, Portugal.

Nephrol Dial Transplant. 1998; 13(12): 3223-5

Publication Types: Case Reports
PMID: 9870498 [PubMed - indexed for MEDLINE]

Descarregar PDF

Hepatitis C virus genotypes and the influence of the induction of immunosuppression with anti-thymocyte globulin (ATG) on chronic hepatitis in renal graft recipients.

Rodrigues A, Pinho L, Lobato L, Queiros A, Castro R, Daniel M, Dias L, Henriques AC, Sarmento A, Guimaraes S.

Nephrology Department, Hospital Geral Santo Antonio, Porto, Portugal.

Transpl Int. 1998; 11 Suppl 1: S115-8

Hepatitis C virus (HCV) exhibits a dramatic genetic variability and several mechanisms of immunological response are unable to control hepatic and extrahepatic replication. Genotype 1 b is associated with more severe clinical manifestations and is less responsive to interferon. In addition, we have reported an increase of HCV RNA viral load after renal transplantation. Anti-thymocyte globulin (ATG) is supposed to increase viral replication and liver dysfunction in chronically infected renal graft recipients. We evaluated the genotype profile in HCV+ patients of our Renal Transplant Unit and studied the effects of ATG, as part of the induction of immunosuppression, on viral load and liver enzymes abnormalities. From 726 renal graft recipients, 104 patients, with a mean follow up of 3.9 +/- 2.9 years, were anti-HCV+ by ELISA II. HCV RNA was measured by quantitative PCR. We correlated the viral load and biochemical liver parameters with genotype, exposure to ATG as induction therapy, early acute rejection episode and the duration of infection. Of the 81 patients tested, 72% were viraemic and genotype 1 b was the predominant viral strain (66%). The majority of these patients (65%) were coinfected by two or more strains. There was no correlation between HCV RNA blood levels and liver enzymes. We did not find higher viral load with genotype 1 b infection (68 +/- 88 mEq/ml vs 75.8 +/- 123 mEq/ml in the others) nor with ATG induction therapy (43.5 +/- 71.3 mEq/ml vs 64.1 +/- 110.5 mEq/ml). Early acute rejection and longer follow up were not associated with higher levels of HCV RNA. The biochemical liver profile showed no relationship with the variables studied. We concluded that genotype 1 b is the predominant strain in our HCV+ population and there is a great prevalence of coinfection with several genotypes. Our results did not confirm a deleterious effect of the use of ATG as induction therapy in these HCV-infected patients. Prospective randomised studies with liver biopsy evaluation are needed to answer more fully the remaining questions about the best immunosuppressive therapy in renal graft recipients with chronic HCV infection.

PMID: 9664959 [PubMed - indexed for MEDLINE]

Login Inicie a sua Sessão
Subscreva a nossa newsletter




Media Partner